更正：B7-H3 CAR-T 细胞清除肝内胆管癌并诱导持久应答

Correction: B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.

B7-H3 CAR-T 细胞根除肝内胆管癌并诱导持久缓解

B7-H3 CAR T cells eradicate intrahepatic cholangiocarcinoma and induce durable response.

这些结果为在晚期 ICC 患者的临床试验中评估 iCas9.B7-H3 CAR-T 细胞策略提供了有力依据。

晚期胆道癌免疫治疗：现状与未来方向

Immunotherapy in advanced biliary tract cancer: current status and future directions.

基于肿瘤免疫微环境的肝内胆管癌免疫治疗进展与挑战

Advances and challenges in immunotherapy for intrahepatic cholangiocarcinoma based on the tumour immune microenvironment.

通过整合机制、临床证据、分子亚型和转化局限性，本综述为 ICC 中生物标志物指导的精准免疫治疗提供了一个平衡的框架。对肝内胆管癌免疫治疗的临床证据和局限性进行了批判性评估，重点强调了对更广泛胆道癌试验的 ICC 特异性解读。将 ICC 肿瘤免疫微环境整合到涉及基质、髓系、淋巴系和代谢调节的功能性免疫轴中。分子亚型和免疫相关生物标志物为 ICC 中生物标志物指导的精准免疫治疗提供了框架。当前 ICC 免疫治疗试验仍受限于异质性设计、ICC

慢性肝病中调控前体耗竭 CD8+ T 细胞的细胞与分子网络：对免疫治疗的启示

Cellular and molecular networks governing precursor exhausted CD8+ T cells in chronic liver disease: Implications for immunotherapy.

靶向 PD-L1 的 CAR-T 细胞对胆管癌表现出强效的抗原特异性活性：一项概念验证研究

CAR-T cells directed toward PD-L1 demonstrate potent, antigen-specific activity against cholangiocarcinoma: A proof of concept study.

胆管癌药物治疗现状：最新进展与关键局限

Current Status of Drug Treatment of Cholangiocarcinoma-Updated Progress and Critical Limitations.

克服异质性与免疫抑制：胆道癌过继性治疗的新策略

Overcoming heterogeneity and immunosuppression: novel strategies in adoptive therapy for biliary tract cancer.

本综述总结了过继性细胞疗法治疗胆道癌的最新进展，并讨论了促进临床转化的优化策略。

同时敲低六种抑制性膜蛋白增强 CAR-T 细胞抗胆管癌活性

Enhancement of CAR-T cell activity against cholangiocarcinoma by simultaneous knockdown of six inhibitory membrane proteins.

我们的结果显示，敲低六重抑制分子的 PTG-T16R-scFV-CAR-T 细胞在体外和体内均表现出对胆管癌的强大免疫力和长期疗效。该策略为胆管癌提供了一种有效且个性化的免疫细胞治疗。

靶向间皮素的 CAR-T 细胞治疗胆管癌的临床前开发

Preclinical development of mesothelin-targeting CAR T cells for the treatment of cholangiocarcinoma.

我们的结果提示，MSLN 是 CCA 中 CAR-T 细胞治疗一个有前景的靶点。